Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Fürth – page 36

543 clinical trials in Fürth, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Fürth at a glance
543
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

543 trials in Fürth

Open in trial search

Study on the Effectiveness and Safety of Litifilimab for Patients with Active Subacute or Chronic Cutaneous Lupus Erythematosus Resistant to Antimalarial Therapy

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Litifilimab
  • Sponsor:Biogen Idec Research Limited

Psoriatic arthropathy

Not recruiting

Study on Upadacitinib for Pain Management in Patients with Psoriatic Arthritis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:Universitaetsklinikum Erlangen AöR

Renal cell carcinoma

Not recruiting

Study of Belzutifan with Lenvatinib versus Cabozantinib in Adults with Advanced Renal Cell Carcinoma Who Have Previously Received Anti-PD-1/L1 Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Breast cancer

Not recruiting

Study of Imlunestrant, Fulvestrant, Exemestane, and Abemaciclib for Patients with Advanced Estrogen Receptor Positive, HER2 Negative Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Eli Lilly & Co.

Study on Benralizumab and Mepolizumab for Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA) Receiving Standard Care

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Benralizumab
  • Sponsor:AstraZeneca AB

Study on TAR-200 and Cetrelimab for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Not Received BCG Treatment

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cetrelimab
  • Sponsor:Janssen Cilag International

Study on the Safety and Effectiveness of Epcoritamab with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Prostate cancer

Not recruiting

Study of Pembrolizumab, Vibostolimab, and Belzutifan for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Merck Sharp & Dohme LLC

Colon cancer stage II+1

Not recruiting

Study on Adjuvant Therapy with Capecitabine for Stage II Colon and Rectal Cancer Patients with Positive ctDNA After Tumor Removal

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Technische Universitat Dresden

Long-Term Study of BI 1015550 for Patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nerandomilast
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study of [177Lu]Lu-NeoB and Capecitabine for Patients with Advanced Breast Cancer Resistant to Hormone Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Novartis Pharma AG

Arteriosclerosis+1

Not recruiting

Study on Reducing Lipoprotein Apheresis with Pelacarsen in Patients with High Lipoprotein(a) and Heart Disease in Germany

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen
  • Sponsor:Novartis Pharma AG

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Fürth

What the registry says about research in the country

01 Breast Cancer Research

Innovative studies focusing on triple-negative breast cancer and HER2-negative variants, exploring new therapeutic approaches with targeted treatments.

  • Advanced treatment combinations
  • Maintenance therapy evaluation
  • Genetic mutation targeting

Multiple trials investigating novel drug combinations for improving patient outcomes.

02 Gastrointestinal Oncology

Research centered on colorectal cancer treatment, including studies for both early-stage and metastatic disease management.

  • Post-resection therapy optimization
  • Circulating tumor DNA analysis
  • Stage II cancer interventions

Examining innovative approaches to improve survival rates in colorectal cancer patients.

03 Cardiovascular Medicine

Studies addressing myocardial infarction and complex cardiac conditions, with emphasis on innovative therapeutic strategies.

  • STEMI treatment protocols
  • Anticoagulation management
  • Post-stent therapy optimization

Investigating new treatments for improved cardiac outcomes and reduced mortality rates.

04 Gynecologic Oncology

Advanced research in ovarian cancer treatment, focusing on maintenance therapy after initial treatment response.

  • Platinum-based therapy enhancement
  • Progression-free survival studies
  • Stage III/IV cancer management

Evaluating innovative maintenance treatments for advanced ovarian cancer patients.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.